Quinn Dinh, MD, Vice President of Medical Affairs at Horizon Therapeutics, discusses areas of research Horizon is focusing on in regard to inebilizumab-cdon (uplizna) and neuromyelitis optica spectrum disorder (NMOSD).
NMOSD is a rare central nervous disorder that primarily affects the spinal cord and optic nerves. Symptoms of NMOSD may include blindness in one or both eyes, weakness or paralysis of arms or legs, spasming, loss of sensation, uncontrollable vomiting and hiccups, and bladder/bowel problems due to spinal cord damage.
As Dr. Dinh mentions, Horizon is currently focused on long-term efficacy of inebilizumab-cdon, particularly in pediatric patients and in pregnancy as NMOSD targets women 10 times more than it does men. Another area they are interested in is the diagnosis of NMOSD. Given that NMOSD patients may wait 10 years for a diagnosis, Horizon is interested in learning about potential biomarkers.
To learn more about NMOSD and other neurological disorders, visit https://checkrare.com/diseases/neurology-nervous-system-diseases/